Blue Trust Inc. Increases Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Blue Trust Inc. boosted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 182.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,189 shares of the company’s stock after acquiring an additional 2,707 shares during the period. Blue Trust Inc.’s holdings in Intellia Therapeutics were worth $94,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its holdings in Intellia Therapeutics by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after purchasing an additional 98,865 shares during the period. Thrivent Financial for Lutherans purchased a new position in shares of Intellia Therapeutics during the 2nd quarter valued at $679,000. American Century Companies Inc. grew its position in shares of Intellia Therapeutics by 23.8% during the 2nd quarter. American Century Companies Inc. now owns 330,514 shares of the company’s stock valued at $7,397,000 after purchasing an additional 63,550 shares in the last quarter. Comerica Bank grew its position in shares of Intellia Therapeutics by 853.6% during the 1st quarter. Comerica Bank now owns 37,105 shares of the company’s stock valued at $1,021,000 after purchasing an additional 33,214 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after purchasing an additional 746,263 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NTLA. Robert W. Baird reduced their price target on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. reduced their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Chardan Capital reduced their price target on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. The Goldman Sachs Group reduced their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $59.13.

Intellia Therapeutics Stock Down 8.3 %

NASDAQ NTLA opened at $14.99 on Wednesday. The company has a 50-day simple moving average of $20.57 and a two-hundred day simple moving average of $22.65. Intellia Therapeutics, Inc. has a 12-month low of $14.70 and a 12-month high of $34.87. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -2.74 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analyst estimates of $19.68 million. During the same period last year, the firm posted ($1.40) EPS. The firm’s revenue for the quarter was down 48.5% on a year-over-year basis. Equities analysts expect that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 3.20% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.